U.S. pharma huge copyright scrapped two experimental weight loss tablets final calendar year—a once-daily tablet, lotiglipron, due to elevated liver enzymes plus a twice-each day capsule, danuglipron, resulting from sturdy Uncomfortable side effects—but CEO Albert Bourla has said the company is determined to “play and get” during the weight